- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01460134
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Study Overview
Status
Conditions
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma
- Marginal Zone B Cell Lymphoma)
- Any T-cell Malignancy
- Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma
- Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer
- Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)
- Burkett's Lymphoma
- Primary Lymphoma of the Central Nervous System
Intervention / Treatment
Detailed Description
CDX-1127 is a fully human monoclonal antibody that binds to a molecule called CD27 found on certain immune cells and also on certain hematologic tumor cells and may act to promote anti-tumor effects.
This study will evaluate the safety and activity of escalating doses of CDX-1127 in patients with B-cell and T-cell hematologic malignancies known to express CD27 and solid tumors that are more likely to be responsive to the immune system.
Eligible patients who enroll in the dose escalation portion of the study will be assigned to one of 5 dose levels of CDX-1127. This first phase of the study will test the safety profile of CDX-1127 and will assess which dose to test in future studies.
During the Expansion phase, cohorts of approximately 15 patients each will receive the study treatment to continue to evaluate the safety profile of CDX-1127 and to determine if it has an effect on their cancer. Expansion cohorts may be limited to one or more tumor types.
Patients enrolled in the study may receive study treatment for up to 5 cycles, until their disease has progressed or until it is necessary to stop the treatment for safety or other reasons.
All patients enrolled in the study will be closely monitored to determine if their cancer is responding to treatment and for any side effects that may occur.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic Arizona - Cancer Clinical Research Unit
-
-
California
-
Stanford, California, United States, 94305
- Stanford Cancer Center - Stanford University
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Abramson Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Dallas, Texas, United States, 75230
- Mary Crowley Cancer Research Centers - Medical City
-
-
Virginia
-
Charlottesville, Virginia, United States, 22908
- University Of Virginia Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Among other criteria, patients must meet the following conditions to be eligible for the study:
- 18 years of age or older.
- Body Weight ≤ 120 kg.
- Histologic diagnosis of either a B-cell or T-cell hematologic malignancy known to express CD27 or one of the following solid tumors: metastatic melanoma, renal (clear) cell carcinoma, hormone-refractory prostate adenocarcinoma, ovarian cancer, colorectal adenocarcinoma or non-small cell lung cancer. For the solid tumor expansion cohorts, enrollment is limited to the following solid tumors: melanoma and renal cell carcinoma.
- Tumor must be recurrent or treatment refractory with no remaining alternative, approved therapy options, with the following exception: melanoma patients enrolled in the expansion phase must have previously received ipilimumab and, for patients with the BRAF V600E mutation, vemurafenib, or have been offered such therapies and refused, and patients must have progressive disease subsequent to previous therapies.
- Measurable or evaluable disease.
- Have adequate blood, bone marrow, liver and kidney function as determined by laboratory tests.
- If of childbearing potential (male or female), agree to practice an effective form of contraception during study treatment.
- Have little or no side effects remaining from prior cancer therapies.
- Provide written informed consent.
Exclusion Criteria:
Among other criteria, patients who meet the following conditions are NOT eligible for the study:
- Known prior primary or metastatic brain or meningeal tumors.
- Receiving treatment with immunosuppressive agents, including any systemic steroids.
- Active infection requiring systemic therapy, known HIV infection, or positive test for hepatitis B surface antigen or hepatitis C.
- Is being treated for anti-coagulation (i.e. warfarin) for reasons other than catheter patency.
- Women who are pregnant or lactating.
- Prior allogeneic bone marrow transplant.
- Autologous bone marrow transplant within 100 days of first dosing.
- Recent chemotherapy or other anti-cancer therapy (within 2 - 14 weeks depending on treatment type).
- Systemic radiation therapy within 4 weeks or prior focal radiotherapy within 2 weeks prior to first dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Hematologic Malignancies (Dose Escalation)
B-Cell Enrollment COMPLETED T-Cell Enrollment COMPLETED
|
Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one "cycle" of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression. The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
Patients will receive 4 weekly doses of CDX-1127 followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
|
EXPERIMENTAL: Solid tumors (Dose Escalation; COMPLETED)
|
Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one "cycle" of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression. The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
Patients will receive 4 weekly doses of CDX-1127 followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
|
EXPERIMENTAL: Solid Tumors (Expansion Phase; COMPLETED)
Several expansion cohorts of up to 15 patients each are planned, including melanoma and renal cell carcinoma.
|
Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one "cycle" of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression. The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
Patients will receive 4 weekly doses of CDX-1127 followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
|
EXPERIMENTAL: Hematologic Malignancies (COMPLETED)
Several expansion cohorts of up to 15 patients each are planned, including Hodgkin lymphoma.
|
Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one "cycle" of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles"). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression. The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127.
Patients will receive 4 weekly doses of CDX-1127 followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period.
All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional "cycles").
Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterize the adverse events associated with CDX-1127 administration
Time Frame: Safety follow up is 70 days from last dose.
|
Analysis of adverse events along with the results of vital sign measurements, physical examinations, and clinical laboratory tests will be used to determine the safety profile of CDX-1127.
|
Safety follow up is 70 days from last dose.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of anti-CD27 antibodies in circulating blood.
Time Frame: Until end of treatment
|
Until end of treatment
|
|
Levels of CDX-1127 in circulating blood.
Time Frame: Until end of treatment
|
Until end of treatment
|
|
Activity Evaluations
Time Frame: Until disease progression
|
Determine the anti-malignant cell activity of CDX-1127 based on change from baseline in tumor measurements every 12 weeks.
|
Until disease progression
|
Immune system effects (eg: lymphoid cell populations and serum cytokine levels)
Time Frame: Until end of treatment
|
Until end of treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2. Erratum In: J Clin Oncol. 2019 Feb 1;37(4):359.
- Ansell SM, Flinn I, Taylor MH, Sikic BI, Brody J, Nemunaitis J, Feldman A, Hawthorne TR, Rawls T, Keler T, Yellin MJ. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4(9):1917-1926. doi: 10.1182/bloodadvances.2019001079.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- non-small cell lung cancer
- ovarian cancer
- solid tumor
- metastatic melanoma
- chronic lymphocytic leukemia
- mantle cell lymphoma
- colorectal adenocarcinoma
- CD27 expressing Hematologic Malignancies
- CD27 expressing Solid Tumors
- Burkett's lymphoma
- primary lymphoma of the central nervous system
- marginal zone B cell lymphoma
- renal (clear) cell carcinoma
- hormone-refractory prostate adenocarcinoma
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Female
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Lung Neoplasms
- Leukemia
- Leukemia, B-Cell
- Neuroendocrine Tumors
- Nevi and Melanomas
- Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Carcinoma, Non-Small-Cell Lung
- Adenocarcinoma
- Ovarian Neoplasms
- Lymphoma, Mantle-Cell
- Lymphoma, B-Cell, Marginal Zone
- Leukemia, Lymphocytic, Chronic, B-Cell
- Melanoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies, Monoclonal
Other Study ID Numbers
- CDX1127-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mantle Cell Lymphoma
-
Northwestern UniversityNational Cancer Institute (NCI); Janssen Scientific Affairs, LLCActive, not recruitingStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma | Stage II Contiguous Mantle Cell Lymphoma | Stage II Non-Contiguous Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell LymphomaUnited States
-
University of WashingtonNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Ann Arbor Stage I Mantle Cell Lymphoma | Ann Arbor Stage II Mantle Cell Lymphoma | Ann Arbor Stage III Mantle Cell Lymphoma | Ann Arbor Stage IV Mantle Cell LymphomaUnited States
-
Burzynski Research InstituteWithdrawnRecurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell LymphomaUnited States
-
BeiGeneRecruitingMantle Cell Lymphoma | Relapsed Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma (MCL)United States, China, Israel, Belgium, Poland, Spain, Turkey, Brazil, Italy, Canada, United Kingdom, France, Germany, Argentina
-
BeiGeneCompletedRefractory Mantle Cell Lymphoma | Relapsed Mantle Cell LymphomaChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMantle Cell Lymphoma | Blastoid Variant Mantle Cell Lymphoma | Pleomorphic Variant Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Central Nervous System Lymphoma | Gastric Mantle Cell Lymphoma | Splenic Mantle Cell LymphomaUnited States
Clinical Trials on CDX-1127
-
National Cancer Institute (NCI)Active, not recruitingPlasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditionsUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingRefractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8United States
-
Nicholas ButowskiCelldex TherapeuticsActive, not recruitingGlioma | Malignant Glioma | Oligodendroglioma | Astrocytoma, Grade II | Glioma, Astrocytic | Oligoastrocytoma, MixedUnited States
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic... and other conditionsUnited States
-
TargetCancer FoundationFoundation MedicineRecruitingCholangiocarcinoma | Cancer of Unknown Primary Site | Rare CancersUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); The Foundation for Barnes-Jewish Hospital; Celldex...TerminatedPancreatic Cancer | Pancreas Cancer | Cancer of the PancreasUnited States
-
Seoul National University HospitalUnknownBreast CancerKorea, Republic of
-
Celldex TherapeuticsCompleted
-
Craig L Slingluff, JrCelldex TherapeuticsCompleted
-
Addario Lung Cancer Medical InstituteRecruiting